Candida auris is spreading through US hospitals faster than public health agencies can contain it. CDC data shows clinical cases tripled from 476 in 2019 to 1,471 in 2023. Screening colonization cases (patients carrying the fungus without symptoms) hit 4,041 in that same year. C. auris has now been detected in healthcare facilities across 29 states. PandemicAlarm would rate this a 3/5 severity event if tracked: not a pandemic threat, but a persistent and worsening healthcare crisis with limited treatment options.
What makes this fungus different?
Most Candida species cause manageable infections. C. auris breaks the mold in three ways that make infectious disease specialists genuinely worried.
First, drug resistance. Some C. auris strains are resistant to all three major classes of antifungal drugs: azoles, echinocandins, and polyenes (amphotericin B). Pan-resistant strains leave physicians with no effective treatment. Roughly 1-2% of US clinical isolates have been pan-resistant so far, but that number is trending upward.
Globally, resistance rates are higher. In India, where C. auris was first identified in 2009, echinocandin resistance in isolates exceeds 30% in some healthcare networks.
Second, environmental persistence. C. auris survives on hospital surfaces (bed rails, IV poles, blood pressure cuffs, doorknobs) for weeks. Standard hospital disinfectants don't reliably kill it. Facilities require specialized cleaning protocols using EPA-registered products effective against C. auris specifically.
Third, identification failures. Standard laboratory methods frequently misidentify C. auris as other Candida species. Only MALDI-TOF mass spectrometry or specific molecular testing reliably distinguishes it. Hospitals without this equipment may harbor undetected C. auris colonization for months before an outbreak is recognized.
Who is at risk?
C. auris overwhelmingly affects people who are already seriously ill. Patients in intensive care units, those with central venous catheters, people who have received prolonged courses of antifungal or antibiotic medications, and residents of long-term care facilities face the highest risk. Bloodstream infections carry a 30-60% mortality rate, though attributing death specifically to C. auris versus the underlying condition is often difficult.
Healthy people visiting hospitals are not at meaningful risk. C. auris is not an airborne pathogen. It spreads through direct contact with contaminated surfaces or person-to-person contact in healthcare settings. You won't catch it at the grocery store.
Why should you care?
The antifungal drug pipeline is nearly empty. Only 3 classes of antifungal drugs exist for treating invasive Candida infections, compared to dozens of antibiotic classes for bacteria. New antifungals in development — rezafungin received FDA approval in 2023, and olorofim and fosmanogepix are in late-stage trials — represent the first new antifungal mechanisms in over a decade. But even optimistic timelines put widespread availability years away.
Meanwhile, C. auris continues its geographic expansion. New states report their first cases every year. Healthcare facilities struggle with containment because colonized patients often show no symptoms and transfer between facilities carries the fungus to new locations.
What should you watch?
Two trends will determine how bad this gets. Geographic expansion into states and facility types where it hasn't yet been detected signals ongoing failure of containment strategies. And rising pan-resistance rates — currently low in the US but higher globally — would turn a serious healthcare problem into a critical one. CDC publishes updated tracking data at cdc.gov/candida-auris. Follow it. The bacteria get all the headlines, but fungi may prove the harder resistance problem to solve.